News · Longevity & Aging
Nurse-led heart failure care cut deaths by 22% across 22 centers in India
Heart failure care in low-resource settings depends on specialists who are scarce and appointments patients cannot reach. A cluster-randomized trial of 1,507 adults moved the work to nurses and phones.
- Deaths over two years fell from about 27% to about 22% with the nurse-led model.
- The chance of spending the whole two years out of hospital rose by about 4.5 points.
- Care was coordinated by nurses and supported by mobile phones, not by more specialists.
- 1,507 adults across 22 centers, and all but one completed two years.
- Most participants had little formal education and over half lived rurally.
The drugs that keep a failing heart going are decades old, off patent, and cheap. What they require is somebody to start them, raise the dose carefully over weeks, and notice when a patient is drifting.
That somebody is usually a cardiologist, and in most of the world there are not enough. A patient who lives three hours from the nearest one does not get titrated; they get admitted when things go wrong.
Moving the work
Writing in Circulation, investigators tested a different arrangement across 22 centers in India. Nurses ran the follow-up, supported by mobile phones for contact and record-keeping, with specialists available behind them.
Centers were randomized rather than patients, which is the correct design when the thing being changed is how a clinic operates. Heart failure with reduced ejection fraction causes high mortality and recurrent hospitalizations in India, and this is the first trial to test whether reorganizing who does the work changes that.
1,507 adults took part, and all but one completed two years.
Who was in it
This is the part that makes the trial unusual. Most participants had little formal education, more than half lived in rural areas, and the commonest cause of their heart failure was coronary disease.
Trials of care models are usually run in well-resourced systems on patients who can already reach a clinic. This one recruited the people the existing arrangement fails.
What changed
Deaths over two years fell from about 27% in usual care to about 22% with the nurse-led model, which the trial reports as a 22% lower mortality risk.
The other measure counted days alive and out of hospital. The chance of getting through the full two years without a single admission rose by roughly four and a half percentage points, and patients in the intervention group had substantially higher odds of a perfect record.
Those two results agree, which matters. A care model that reduced admissions without touching mortality could simply mean people were being kept out of hospital when they needed to be in it.
Why it plausibly works
Nothing here is mysterious. Heart failure treatment is a titration problem: several drugs, each started low and increased as blood pressure and kidney function allow, with the gains arriving only at the higher doses.
Left to routine care, most patients never reach those doses, not because anyone disagrees about the target but because nobody has the appointments to get there. A nurse with a phone and a protocol has the appointments.
The limits
Open-label, necessarily. You cannot blind a clinic to whether it is running a new care model, and knowing can change how readily a patient is admitted. Mortality is the outcome least vulnerable to that, and mortality moved.
Twenty-two centers in one country is also a specific setting. The size of the benefit depends on how far usual care falls short to begin with, so a system that already titrates well has less room to gain from this.
And a trial can fund a nurse for two years. Whether a health system sustains that post is a different question, and it is the one that usually decides whether a result like this changes anything.
What it adds
Heart failure means your heart can’t pump enough blood for your body’s needs, and the global response has concentrated on finding better drugs.
This points somewhere less glamorous. In settings where the drugs already exist and the specialists do not, the reachable gain is in delivery, and the trial puts a number on it: about five fewer deaths for every hundred patients over two years, achieved by changing who makes the phone calls.
People also ask
What did the trial find?
Among 1,507 adults, the probability of surviving 730 days without hospitalization was 84.0% (95% CI, 82.2%-85.8%) in the intervention group against 79.4% (77.7%-81.2%) in usual care. There were 163 deaths (21.59%) in the intervention group against 201 (26.73%) in usual care (risk ratio 0.80; 95% CI 0.67-0.97), and a 22% lower mortality risk in the Cox model (hazard ratio 0.78; 0.63-0.95; P = 0.028).
What is a collaborative care model?
A way of organizing chronic disease care so that a trained non-specialist, here a nurse, handles the routine follow-up, medication adjustment and monitoring, with a specialist available for decisions that need one. It moves work to where the staff actually are.
What does days alive and out of hospital mean?
A single measure that counts the days a person is both alive and not in a hospital bed. It penalizes death and admission together, which reflects what patients care about better than counting either alone.
Why does this matter more outside wealthy countries?
Because the shortage is specialists, not knowledge. The treatments for heart failure with reduced pumping function are established and mostly inexpensive; what is missing is somebody to titrate them and check on people between appointments.
What is a cluster-randomized trial?
One where whole sites are randomized rather than individual patients. It is the right design when the intervention changes how a clinic works, because you cannot run two systems of care in the same building without them contaminating each other.
Was this a drug trial?
No. Both groups received the same medicines. What differed was who followed the patients up, how often, and with what support, which is why the result is about delivery rather than about a treatment.
Does this apply to health systems elsewhere?
The size of the benefit depends on how far usual care falls short, so a system with good routine follow-up has less room to gain. This is general information rather than medical advice.